SEC Tracker
Get the app

Arcutis Biotherapeutics ARQT

Arcutis appoints Dr. Robert Scott to board

Item 5.02 Executive or director change, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Board increased to 11 directors
  2. Dr. Robert Scott appointed as Class II director
  3. Received stock option award for 20,507 shares
  4. Compensation includes $350,000 equity award and $50,000 cash retainer

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Arcutis Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Ligand Pharmaceuticals LGND public float $1.6B, Jun 30, 2025
  2. Ocular Therapeutix OCUL public float $1.6B, Jun 30, 2025
  3. Arrowhead Pharmaceuticals ARWR public float $1.4B, Mar 31, 2025, over 18 months old
  4. Sarepta Therapeutics SRPT public float $1.7B, Jun 30, 2025
  5. Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025